Sec Form 3 Filing - de la Huerta Martinez Maria del Pilar @ Biofrontera Inc. - 2025-09-16

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person de la Huerta Martinez Maria del Pilar 2. Issuer Name and Ticker or Trading Symbol Biofrontera Inc. [ BFRI] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) HEMMELRATHER WEG 201 3. Date of Earliest Transaction (MM/DD/YY) 09/16/2025 (Street) LEVERKUSEN, 2MD-51377 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 400,000 I By Biofrontera AG ( 1 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series D Convertible Preferred Stock $ 0.0006 ( 2 ) ( 2 ) Common Stock 4,831,172 I By Biofrontera AG ( 1 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other de la Huerta Martinez Maria del Pilar HEMMELRATHER WEG 201 LEVERKUSEN, 2MD-51377 X X Signatures /s/ Maria del Pilar de la Huerta Martinez 09/25/2025 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The reported shares are held directly by Biofrontera AG. The Reporting Person may be deemed to beneficially own the shares owned by Biofrontera AG because of her position as the sole member of the management board of Biofrontera AG. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of her indirect pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. ( 2 )The convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date.

Remarks: Biofrontera AG has entered into an agreement with the Issuer pursuant to which Biofrontera AG may appoint one representative to the board of directors of the Issuer. Dr. Heikki Lanckriet has been deputized to represent Biofrontera AG on the board of directors of the Issuer. By virtue of Dr. Lanckriet's representation and the Reporting Person's position as the sole member of the management board of Biofrontera AG, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed a director by deputization of the Issuer. Dr. Lanckriet has filed a separate Section 16 report disclosing securities of the Issuer he may be deemed to beneficially own for Section 16 purposes.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.